Asset Details
Do you wish to reserve the book?
Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease
Do you wish to request the book?
Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease
2019
Overview
In a randomized trial, patients with brain amyloid deposition but no dementia who received a β-site amyloid precursor protein–cleaving enzyme 1 inhibitor had no benefit with respect to clinical outcomes and worsening on some measures of cognition and daily function.
Publisher
Massachusetts Medical Society
Subject
/ Alzheimer Disease - prevention & control
/ Amyloid beta-Peptides - analysis
/ Amyloid beta-Protein Precursor - antagonists & inhibitors
/ Cognitive Dysfunction - drug therapy
/ Cognitive Dysfunction - pathology
/ Cyclic S-Oxides - adverse effects
/ Cyclic S-Oxides - therapeutic use
/ Dementia
/ Enzyme Inhibitors - adverse effects
/ Enzyme Inhibitors - therapeutic use
/ Enzymes
/ Female
/ Humans
/ Male
/ Memory
/ NMR
/ Plaque, Amyloid - diagnostic imaging
/ Positron-Emission Tomography
/ Thiadiazines - adverse effects
/ Thiadiazines - therapeutic use
